PHARMACOLOGICAL INNOVATIONS AND NEUROSCIENCES IN HEALTHCARE
DOI:
https://doi.org/10.59087/biofarma.v4i1.37Keywords:
Pharmaceutical Process, pharmacology, innovationAbstract
This article discusses emerging innovations in drug treatments, exploring their intersection with neuroscientific discoveries. We analyze the impact of these innovations on nursing practices and public health policies, emphasizing the need to adapt professional training and health systems to maximize benefits for the population. We discuss contemporary challenges such as drug resistance, the growing need for holistic approaches to patient care, and the use of technology for monitoring and interventions.
Downloads
References
Dou, H., et al. (2018). The clinical significance of Alzheimer’s disease blood biomarkers. Neurology.
Fava, M., & Davidson, K. G. (1996). Definition and epidemiology of treatment-resistant depression. Journal of Clinical Psychiatry.
Ferreira, J. J., & Ferreira-Vieira, T. H. (2023). Alzheimer's Disease: Recent Progress in Pharmacological Treatments. Journal of Neuroscience.
Hernández, A., et al. (2019). Inequities in access to innovative medicines: The case of biologics. International Journal for Equity in Health.
Hester, R. K., et al. (2020). Telemedicine for Patients with Infectious Diseases: A Promising Approach. Telemedicine Journal and e-Health.
Huang, H., et al. (2021). The effects of continuing education on nurses' clinical competences in Taiwan. Journal of Nursing Education.
Kleinman, A. (2023). "Social Factors in Health." Health Psychology Review.
Kuo, C. C., et al. (2020). Understanding treatment-resistant depression: a guide for therapists. Lancet Psychiatry.
Li, Y., et al. (2022). The capacity of a blood test to predict the presence of amyloid beta protein associated with Alzheimer’s disease in the brain. Neurology.
Sevigny, J., Chiao, P., Bussière, T., et al. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. New England Journal of Medicine.
Souza, R. S., & Menegucci, D. R. (2023). O Diagnóstico de Alzheimer e Comprometimento Cognitivo: Julgamento clínico e tratamento. BSC-Biofarma Study Center.
WHALEN, M., et al. (2016). Clinical applications of the emerging biomarkers in Alzheimer’s Disease. Alzheimer's & Dementia.
WHO. (2021). Guidelines for clinical management and research on pharmacological treatments for mental disorders.
Zanos, P., et al. (2018). The ketamine experience: a clinical guide. American Journal of Psychiatry.
-
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Biofarma - Multidisciplinary Scientific Journal of Biology, Pharmacy and Health
This work is licensed under a Creative Commons Attribution 4.0 International License.
You have the right to:
*Click on the license image above for more details.
